# Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDP

> **NCT01225276** · PHASE2,PHASE3 · TERMINATED · sponsor: **Octapharma** · enrollment: 2 (actual)

## Conditions studied

- Chronic Inflammatory Demyelinating Polyradiculoneuropathy

## Interventions

- **DRUG:** NewGam 10%
- **DRUG:** Placebo
- **DRUG:** NewGam 10%
- **DRUG:** NewGam 10%

## Key facts

- **NCT ID:** NCT01225276
- **Lead sponsor:** Octapharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-10
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Study Terminated.priority changes in product development.
- **Last updated:** 2017-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01225276

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01225276, "Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDP". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01225276. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*